About International Stem Cell (OTCMKTS:ISCO)
International Stem Cell Corporation (ISCO) is a biotechnology company. The Company is focused on therapeutic and biomedical product development. The Company's segments include Therapeutic Market, Cosmetic Market and Biomedical Market. The Company's subsidiaries include International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases, such as Parkinson's disease, liver diseases and corneal blindness; Cyto Therapeutics, PTY LTD, a research and development company, for the Therapeutic Market; Lifeline Skin Care, Inc. for the Cosmetic Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells, and Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$7.16 million
Price / Sales0.93
Price / CashN/A
Book Value$0.87 per share
Price / Book1.84
Return on Equity-184.54%
Return on Assets-33.09%
International Stem Cell (OTCMKTS:ISCO) Frequently Asked Questions
What is International Stem Cell's stock symbol?
International Stem Cell trades on the OTCMKTS under the ticker symbol "ISCO."
How were International Stem Cell's earnings last quarter?
International Stem Cell Corp (OTCMKTS:ISCO) posted its earnings results on Monday, August, 14th. The biotechnology company reported ($0.25) EPS for the quarter. The biotechnology company had revenue of $1.76 million for the quarter. International Stem Cell had a negative return on equity of 184.54% and a negative net margin of 34.49%. View International Stem Cell's Earnings History.
When will International Stem Cell make its next earnings announcement?
Who are some of International Stem Cell's key competitors?
Some companies that are related to International Stem Cell include OpGen (OPGN), SenesTech (SNES), Jaguar Health (JAGX), Cytori Therapeutics (CYTX), Acura Pharmaceuticals (ACUR), Dextera Surgical (DXTR), Bio Blast Pharma (ORPN), ESSA Pharma (EPIX), Lombard Medical (EVARF), Secure Point Technologies (IMSC), Mateon Therapeutics (MATN), Strata Skin Sciences (SSKN), Roka Bioscience (ROKA), NeuroMetrix (NURO), Rosetta Genomics (ROSG), TearLab (TEAR), Tetralogic Pharmaceuticals (TLOG) and Affymax (AFFY).
Who are International Stem Cell's key executives?
International Stem Cell's management team includes the folowing people:
- Andrey Semechkin Ph.D., Co-Chairman of the Board, Chief Executive Officer
- Donald Arthur Wright, Independent Co-Chairman of the Board
- Jennifer Stephens, Chief Financial Officer
- Russell Kern Ph.D., Executive Vice President, Chief Scientific Officer
- Charles J. Casamento, Executive Director and Principal, The Sage Group
- Paul V. Maier, Independent Director
How do I buy International Stem Cell stock?
Shares of International Stem Cell can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is International Stem Cell's stock price today?
One share of International Stem Cell stock can currently be purchased for approximately $1.60.
How big of a company is International Stem Cell?
International Stem Cell has a market capitalization of $6.23 million and generates $7.16 million in revenue each year. The biotechnology company earns $-1,070,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. International Stem Cell employs 38 workers across the globe.
How can I contact International Stem Cell?
International Stem Cell's mailing address is 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008. The biotechnology company can be reached via phone at 760-940-6383 or via email at [email protected]
MarketBeat Community Rating for International Stem Cell (ISCO)MarketBeat's community ratings are surveys of what our community members think about International Stem Cell and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
International Stem Cell (OTCMKTS:ISCO) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
International Stem Cell (OTCMKTS:ISCO) Earnings History and Estimates Chart
International Stem Cell (OTCMKTS ISCO) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/4/2018|| || || || || || || || |
|8/14/2017||Q2 2017||($0.25)||$1.76 million||View||N/A|
|5/17/2017||Q1 2017||($0.78)||$2.01 million||View||N/A|
|11/14/2016||Q3 2016||($0.30)||$1.94 million||View||N/A|
|11/13/2014||Q3 2014||($0.01)||($0.01)||$1.90 million||$1.96 million||View||N/A|
|8/12/2014||Q2 2014||($0.01)||($0.01)||$1.85 million||$1.59 million||View||N/A|
International Stem Cell (OTCMKTS:ISCO) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for International Stem Cell (OTCMKTS:ISCO)
No dividend announcements for this company have been tracked by MarketBeat.com
International Stem Cell (OTCMKTS ISCO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 82.32%
International Stem Cell (OTCMKTS ISCO) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/8/2017||Wright Don||Director||Sell||18,639||$1.50||$27,958.50|| |
|12/7/2017||Andrey Semechkin||CEO||Buy||1,860,810||$1.75||$3,256,417.50|| |
|5/22/2017||Andrey Semechkin||CEO||Buy||3,200||$1.64||$5,248.00|| |
|3/22/2017||Andrey Semechkin||CEO||Buy||10,000||$1.67||$16,700.00|| |
|3/14/2017||Andrey Semechkin||CEO||Buy||8,100||$1.41||$11,421.00|| |
|12/8/2016||Andrey Semechkin||CEO||Buy||285,714||$1.75||$499,999.50|| |
|9/14/2016||Andrey Semechkin||CEO||Buy||200,000||$1.75||$350,000.00|| |
|8/22/2016||Andrey Semechkin||CEO||Buy||154,285||$1.75||$269,998.75|| |
|6/29/2016||Andrey Semechkin||CEO||Buy||215,000||$1.75||$376,250.00|| |
|8/6/2014||Ruslan Semechkin||Major Shareholder||Buy||1,000,000||$0.10||$100,000.00|| |
|1/22/2013||Andrey Semechkin||CEO||Buy||10,000,000||$0.20||$2,000,000.00|| |
International Stem Cell (OTCMKTS ISCO) News Headlines
|International Stem Cell Corp (ISCO) CEO Andrey Semechkin Bought $3.3 million of Shares|
finance.yahoo.com - December 9 at 11:08 AM
|International Stem Cell Corp. (ISCO) Director Wright Don Sells 18,639 Shares|
www.americanbankingnews.com - December 8 at 6:22 PM
|Insider Buying: International Stem Cell Corp. (ISCO) CEO Buys $3,256,417.50 in Stock|
www.americanbankingnews.com - December 8 at 5:30 PM
|International Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's Disease|
finance.yahoo.com - November 29 at 11:14 AM
|International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017|
finance.yahoo.com - November 18 at 2:39 AM
|BRIEF-International Stem Cell Corp posts positive interim clinical results for Parkinson's disease clinical trial|
www.reuters.com - November 13 at 4:20 PM
|International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson's Disease Clinical Trial|
finance.yahoo.com - November 13 at 4:20 PM
|International Stem Cell Corporation to Present Six-Month Results of Neural Stem Cell Transplantation for Parkinson's Disease at Neuroscience 2017|
finance.yahoo.com - November 8 at 10:40 AM
|International Stem Cell Corporation Receives Key Stem Cell Patent in Australia|
finance.yahoo.com - October 31 at 11:59 PM
|International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted to Treat Liver Diseases|
finance.yahoo.com - October 9 at 7:59 PM
|Company Uses Patients' Own Cells To Put An End To Baldness, Aging Skin And Tendon Degeneration|
www.forbes.com - September 29 at 10:11 PM
|International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and ... - GlobeNewswire (press release)|
globenewswire.com - September 28 at 9:12 PM
|SA biotech headed west to try and score potential clients and cash|
www.bizjournals.com - September 27 at 4:57 PM
|BRIEF-International Stem Cell to expand its revenue generating biomedical businesses|
www.reuters.com - September 26 at 5:05 PM
|International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and Future Clinical Trials|
finance.yahoo.com - September 26 at 10:18 AM
|"Stem Cell Therapy: A Rising Tide - How Stem...|
www.benzinga.com - September 20 at 9:33 PM
|Cellular Dynamics International Signs Agreement with Nanion Technologies to Enhance Mutual Offerings for Researchers|
www.businesswire.com - September 20 at 9:33 PM
|International Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical Trial|
finance.yahoo.com - September 20 at 4:31 PM
|International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017|
finance.yahoo.com - September 18 at 7:30 PM
|International Stem Cell Corporation Reports Progress in Phase I Clinical Trial for Parkinson's Disease|
finance.yahoo.com - September 7 at 8:29 PM
|FDA cracks down on stem cell clinics|
www.cnn.com - August 29 at 12:39 AM
|International Stem Cell Corp. (ISCO) Releases Quarterly Earnings Results|
www.americanbankingnews.com - August 15 at 9:52 AM
|International Stem Cell Corporation Announces Operating Results for the Three and Six-Months ended June 30, 2017|
finance.yahoo.com - August 14 at 11:09 PM
|BRIEF-International Stem Cell receives approval to start second patient cohort in clinical trial for Parkinson’s disease|
www.reuters.com - May 11 at 11:35 PM
|Stem Cells Market 2022 Global Trends and Analysis Research Report Now Available at ReportsnReports.com|
www.marketwatch.com - May 11 at 11:35 PM
|3 Things In Biotech You Should Learn Today: April 27, 2017|
seekingalpha.com - April 28 at 6:57 PM
|INTERNATIONAL STEM CELL CORP Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 31 at 6:00 PM
|INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - March 1 at 11:39 AM
|INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and|
biz.yahoo.com - January 18 at 6:31 PM
|BRIEF-International Stem Cell Q3 revenue falls 9 pct to $1.94 mln|
www.reuters.com - November 16 at 5:57 PM
|Edison Issues Update on International Stem Cell (ISCO)|
www.prnewswire.com - August 2 at 10:30 AM
|ISC-hpNSC transplantation is being evaluated for the treatment of Parkinson’s Disease|
globenewswire.com - July 28 at 8:45 AM
|Stem Cell Partnership: Patient Advocates And Scientists At The International Society For Stem Cell Research Convention|
www.huffingtonpost.com - July 10 at 5:17 PM
|INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Unregistered Sale of Equity Securities|
biz.yahoo.com - July 6 at 2:08 PM
|International Stem Cell Corp (ISCO.PK)|
www.reuters.com - June 17 at 5:36 PM
International Stem Cell (OTCMKTS:ISCO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
International Stem Cell (OTCMKTS ISCO) Stock Chart for Tuesday, December, 12, 2017